Literature DB >> 12522067

The anti-relapse compound acamprosate inhibits the development of a conditioned place preference to ethanol and cocaine but not morphine.

Andrew J McGeehan1, M Foster Olive.   

Abstract

The effects of the anti-relapse compound acamprosate (calcium acetylhomotaurinate) on the conditioned rewarding effects of ethanol, cocaine and morphine were studied using the conditioned place preference (CPP) paradigm. During 3 days of drug conditioning, mice were pretreated with saline or acamprosate (30, 100 or 300 mg kg(-1) i.p.) 10 min prior to the administration of ethanol (2 g kg(-1) i.p.), cocaine (15 mg kg(-1) i.p.) or morphine (10 mg kg(-1) i.p.), and subsequently confined to one of two distinct conditioning chambers. On the following day, mice were tested for the expression of CPP. Acamprosate dose-dependently reduced the development of CPP to ethanol and cocaine but not morphine. When tested as the conditioning drug, acamprosate alone produced neither a conditioned place preference nor aversion. These data suggest that acamprosate can suppress the conditioned rewarding effects of ethanol and certain classes of abused substances.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12522067      PMCID: PMC1573657          DOI: 10.1038/sj.bjp.0705059

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  23 in total

1.  The anti-craving compound acamprosate acts as a weak NMDA-receptor antagonist, but modulates NMDA-receptor subunit expression similar to memantine and MK-801.

Authors:  G Rammes; B Mahal; J Putzke; C Parsons; P Spielmanns; E Pestel; R Spanagel; W Zieglgänsberger; J Schadrack
Journal:  Neuropharmacology       Date:  2001-05       Impact factor: 5.250

2.  Acamprosate reduces context-dependent ethanol effects.

Authors:  Etienne Quertemont; Christian Brabant; Philippe De Witte
Journal:  Psychopharmacology (Berl)       Date:  2002-08-08       Impact factor: 4.530

Review 3.  Ethanol and amino acids in the central nervous system: assessment of the pharmacological actions of acamprosate.

Authors:  A Dahchour; P De Witte
Journal:  Prog Neurobiol       Date:  2000-03       Impact factor: 11.685

Review 4.  Treatment of alcohol-dependent outpatients with acamprosate: a clinical review.

Authors:  B J Mason
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

Review 5.  Neuropharmacological treatments for alcoholism: scientific basis and clinical findings.

Authors:  B A Johnson; N Ait-Daoud
Journal:  Psychopharmacology (Berl)       Date:  2000-05       Impact factor: 4.530

Review 6.  Theories of drug craving, ancient and modern.

Authors:  D C Drummond
Journal:  Addiction       Date:  2001-01       Impact factor: 6.526

7.  Effects of acamprosate and scopolamine on the working memory of rats in a three-panel runway task.

Authors:  I Okulicz-Kozaryn; P Midolajczak; K Szczawinska; E Kaminska; K Kus
Journal:  J Basic Clin Physiol Pharmacol       Date:  2001

8.  Pharmacokinetics of systemically administered cocaine and locomotor stimulation in mice.

Authors:  M Benuck; A Lajtha; M E Reith
Journal:  J Pharmacol Exp Ther       Date:  1987-10       Impact factor: 4.030

9.  Reinforcing and discriminative stimulus effects of Ca-acetyl homotaurine in animals.

Authors:  K A Grant; W L Woolverton
Journal:  Pharmacol Biochem Behav       Date:  1989-03       Impact factor: 3.533

10.  Effects of acamprosate and some polyamine site ligands of NMDA receptor on short-term memory in rats.

Authors:  Przemyslaw Mikolajczak; Irena Okulicz-Kozaryn; Ewa Kaminska; Lidia Niedopad; Anna Polanska; Joanna Gebka
Journal:  Eur J Pharmacol       Date:  2002-05-24       Impact factor: 4.432

View more
  21 in total

Review 1.  Recent advances in the development of treatments for alcohol and cocaine dependence: focus on topiramate and other modulators of GABA or glutamate function.

Authors:  Bankole A Johnson
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  The clinical pharmacology of acamprosate.

Authors:  Nicola J Kalk; Anne R Lingford-Hughes
Journal:  Br J Clin Pharmacol       Date:  2014-02       Impact factor: 4.335

3.  Sex-specific effects of developmental alcohol exposure on cocaine-induced place preference in adulthood.

Authors:  Victoria A Macht; Sandra J Kelly; Justin T Gass
Journal:  Behav Brain Res       Date:  2017-06-06       Impact factor: 3.332

Review 4.  Cocaine-induced neuroadaptations in glutamate transmission: potential therapeutic targets for craving and addiction.

Authors:  Heath D Schmidt; R Christopher Pierce
Journal:  Ann N Y Acad Sci       Date:  2010-02       Impact factor: 5.691

5.  A double-blind, placebo-controlled pilot trial of acamprosate for the treatment of cocaine dependence.

Authors:  Kyle M Kampman; Charles Dackis; Helen M Pettinati; Kevin G Lynch; Thorne Sparkman; Charles P O'Brien
Journal:  Addict Behav       Date:  2010-11-10       Impact factor: 3.913

6.  Acamprosate attenuates cocaine- and cue-induced reinstatement of cocaine-seeking behavior in rats.

Authors:  M Scott Bowers; Billy T Chen; Jonathan K Chou; Megan P H Osborne; Justin T Gass; Ronald E See; Antonello Bonci; Patricia H Janak; M Foster Olive
Journal:  Psychopharmacology (Berl)       Date:  2007-09-02       Impact factor: 4.530

7.  α6 subunit-containing nicotinic receptors mediate low-dose ethanol effects on ventral tegmental area neurons and ethanol reward.

Authors:  Scott C Steffensen; Samuel I Shin; Ashley C Nelson; Stephanie S Pistorius; Stephanie B Williams; Taylor J Woodward; Hyun Jung Park; Lindsey Friend; Ming Gao; Fenfei Gao; Devin H Taylor; M Foster Olive; Jeffrey G Edwards; Sterling N Sudweeks; Lori M Buhlman; J Michael McIntosh; Jie Wu
Journal:  Addict Biol       Date:  2017-09-13       Impact factor: 4.280

Review 8.  The Nucleus Accumbens: Mechanisms of Addiction across Drug Classes Reflect the Importance of Glutamate Homeostasis.

Authors:  M D Scofield; J A Heinsbroek; C D Gipson; Y M Kupchik; S Spencer; A C W Smith; D Roberts-Wolfe; P W Kalivas
Journal:  Pharmacol Rev       Date:  2016-07       Impact factor: 25.468

9.  Acamprosate attenuates the handling induced convulsions during alcohol withdrawal in Swiss Webster mice.

Authors:  Ben Lewis; Dennis J Morrell; Justin M Farook; Ali Krazem; John M Littleton; Susan Barron
Journal:  Physiol Behav       Date:  2008-06-06

10.  Combined Effects of Acamprosate and Escitalopram on Ethanol Consumption in Mice.

Authors:  Ada Man-Choi Ho; Yanyan Qiu; Yun-Fang Jia; Felipe S Aguiar; David J Hinton; Victor M Karpyak; Richard M Weinshilboum; Doo-Sup Choi
Journal:  Alcohol Clin Exp Res       Date:  2016-05-17       Impact factor: 3.455

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.